Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience

Blood

Volumn 117, Issue 16, 2011, Pages 4367-4375

  Slatter, Mary A ^a   Rao, Kanchan ^b   Amrolia, Persis ^b   Flood, Terry ^a   Abinun, Mario ^a   Hambleton, Sophie ^a   Nademi, Zohreh ^a   Goulden, Nick ^b   Davies, Graham ^b   Qasim, Waseem ^b   Gaspar, Hubert B ^b   Cant, Andrew ^a   Gennery, Andrew R ^a   Veys, Paul ^b  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ARTICLE; BRAIN HEMORRHAGE; CARTILAGE HAIR HYPOPLASIA; CARTILAGE HYPOPLASIA; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC GRANULOMATOUS DISEASE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SAFETY; ENTEROVIRUS INFECTION; FAMILY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IPEX SYNDROME; LEUKOCYTE ADHESION DEFICIENCY; LONG TERM CARE; LOW DRUG DOSE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; ORGAN DONOR; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIMARY IMMUNODEFICIENCY DISORDER; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; SEVERE COMBINED IMMUNODEFICIENCY; SIBLING; SKIN TOXICITY; SKIN ULCER; T LYMPHOCYTE; TREATMENT OUTCOME; UNITED KINGDOM; VEIN OCCLUSION; WISKOTT ALDRICH SYNDROME;

EID: 79956040256     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-312082     Document Type: Article

References (30)

1. Wynn RF, Boelens JJ. Bone-marrow transplantation in non-malignant disease. Lancet. 2009; 374(9693):856-858.
2. Veys P. Reduced intensity transplantation for primary immunodeficiency disorders. Immunol Allergy Clin North Am. 2010;30(1):103-124.
3. Gennery AR, Slatter MA, Grandin L, et al. Transplantation of haematopoietic stem cells and longterm survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126(3):602-610.
4. Rao K, Amrolia PJ, Jones A, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood. 2005;105(2):879-885. (Pubitemid 40070779)
5. Straathof KC, Rao K, Eyrich M, et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009;374(9693):912-920.
6. Ritchie DS, Seymour JF, Roberts AW, Szer J, Grigg AP. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplant. 2001;28(1):101-103. (Pubitemid 32707626)
7. Burroughs LM, Storb R, Leisenring WM, et al. Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders. Bone Marrow Transplant. 2007;40(7):633-642. (Pubitemid 47456477)
8. Sjoo F, Hassan Z, Abedi-Valugerdi M, et al. Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol. 2006;34(1):115-121. (Pubitemid 43069608)
9. Greystoke B, Bonanomi S, Carr TF, et al. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol. 2008; 142(2):257-262. (Pubitemid 351987307)
10. Beelen DW, Trenschel R, Casper J, et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimenrelated complications. Bone Marrow Transplant. 2005;35(3):233-241. (Pubitemid 40268293)
11. Casper J, Freund M. Treosulfan based conditioning for autologous and allogeneic hematopoietic stem cell transplantation. Int J Clin Pharmacol Ther. 2004;42(11):661-662.
12. Casper J, Knauf W, Kiefer T, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood. 2004;103(2):725-731. (Pubitemid 38140111)
13. Glowka FK, Romanski M, Wachowiak J. Highdose treosulfan in conditioning prior to hematopoietic stem cell transplantation. Expert Opin Investig Drugs. 2010;19(10):1275-1295.
14. Klaudel-Dreszler MA, Kalwak K, Kurenko-Deptuch M, et al. Treosulfan-based conditioning regimen in a second matched unrelated peripheral blood stem cell transplantation for a pediatric patient with CGD and invasive aspergillosis, who experienced initial graft failure after RIC. Int J Hematol. 2009;90(5):571-575.
15. Cutting R, Mirelman A, Vora A. Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation. Br J Haematol. 2008;143(5):748-751.
16. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003;101(5):2043-2048. (Pubitemid 36237612)
17. Kroger N, Schetelig J, Zabelina T, et al.Afludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant. 2001;28(7): 643-647. (Pubitemid 33014597)
18. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756-763. (Pubitemid 28078275)
19. Bacher U, Klyuchnikov E, Wiedemann B, Kroeger N, Zander AR. Safety of conditioning agents for allogeneic haematopoietic transplantation. Expert Opin Drug Saf. 2009;8(3):305-315.
20. Akasheh MS, Freytes CO, Vesole DH. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2000; 26(10):1107-1109.
21. Bruno B, Souillet G, Bertrand Y,Werck-Gallois MC, So Satta A, Bellon G. Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre. Bone Marrow Transplant. 2004;34(2):143-147. (Pubitemid 39077105)
22. van PelM, van BreugelDW, VosW, Ploemacher RE, Boog CJ. Towards amyeloablative regimen with clinical potential: I. Treosulfan conditioning and bonemarrow transplantation allow induction of donor-specific tolerance for skin grafts across fullMHCbarriers. Bone Marrow Transplant. 2003;32(1):15-22. (Pubitemid 36850275)
23. Ploemacher RE, Johnson KW, Rombouts EJ, et al. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant. 2004;10(4):236-245. (Pubitemid 38456202)
24. Rao K, Adams S, Goulden N, et al. Peripheral blood is the stem cell source of choice for reduced intensity stem cell transplant in children. Biol Blood Marrow Transplant. 2010;16(suppl 2): S183.
25. Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott- Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood. 2008;111(1):439-445.
26. Glowka FK, Karazniewicz-Lada M, Grund G, Wrobel T, Wachowiak J. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. Bone Marrow Transplant. 2008;42(suppl 2):S67-S70.
27. Glowka FK, Lada MK, Grund G, Wachowiak J. Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;850(1):569-574. (Pubitemid 46618191)
28. Horn B, Baxter-Lowe LA, Englert L, et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant. 2006;37(3):263-269.
29. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet. 2004;364(9429):156-162. (Pubitemid 38891687)
30. Seger RA. Modern management of chronic granulomatous disease. Br J Haematol. 2008; 140(3):255-266.